Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

ORKA

Insider Sentiment (TTM):

Last Purchase:2025-02-14Last Sale:2026-06-22Shares Purchased (TTM):0Shares Sold (TTM):209,962

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:51,586,208Shares Outstanding:55,172,410Institutional Ownership Pct.:93.50%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Series A Convertible Preferred Stock	-	-	-	-	-	-	0	-	-	-	-	-
Series B Non Voting Convertible Preferred Stock Am…	-	0	0	0	0	0	0	-	-	-	-	-
Related Party	-	3	0	7	2	1	6	8	-	-	-	0
Assets
Series A Non Voting Convertible Preferred Stock	-	-	-	-	-	-	0	0	-	-	-	-
Series B Non Voting Convertible Preferred Stock	-	-	-	-	-	-	-	0	-	-	-	-
Assets Current
Other Assets Current	-	-	-	-	-	-	-	-	1	1	0	0
Cash And Cash Equivalents At Carrying Value	268	50	47	91	65	84	62	411	33	36	37	38
Marketable Securities Current	605	339	290	258	263	266	314	-	-	-	-	-
Prepaid Expense And Other Assets Current	11	6	7	6	4	3	1	2	-	-	-	-
Assets Current	885	395	344	355	332	352	377	413	34	37	38	39
Marketable Securities Noncurrent	252	107	143	152	23	24	18	-	-	-	-	-
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	2	2	2	2	2	1	1	1	0	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	1,139	504	489	509	357	377	396	414	34	37	38	39
Liabilities And Stockhold…
Liabilities Current
Other Accrued Liabilities Current	-	-	-	-	-	-	-	-	1	1	0	1
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	0.001	-
Preferred Stock Shares Authorized	-	-	-	-	-	-	-	-	-	-	5	-
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	-	0	-
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0	-
Accounts Payable Trade Current	8	4	4	2	5	4	3	2	1	1	0	0
Employee Related Liabilities Current	-	-	-	-	-	-	-	-	0	0	0	0
Accrued Liabilities And Other Liabilities	14	9	11	9	4	6	3	2	-	-	-	-
Operating Lease Liability Current	1	1	1	0	1	0	0	0	-	-	-	-
Liabilities Current	23	17	15	21	12	12	13	18	1	2	1	1
Operating Lease Liability Noncurrent	2	1	1	1	2	1	1	1	0	0	0	0
Liabilities	25	18	17	22	14	12	14	19	1	2	1	1
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,375	705	658	643	470	466	463	397	226	226	226	226
Accumulated Other Comprehensive Income Loss Net Of…	-2	-0	1	0	-0	-0	-0	-	-	-	-	-
Retained Earnings Accumulated Deficit	-262	-221	-189	-160	-129	-105	-84	-58	-193	-191	-189	-188
Stockholders Equity	1,115	487	472	487	344	365	382	342	-29	-7	37	38
Liabilities And Stockholders Equity	1,139	504	489	509	357	377	396	414	34	37	38	39
Series A Preferred Stock	-	-	-	-	-	-	-	-20	-	-	-	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	545	545	545	545	545	545	545	545	100	100	100	100
Common Stock Shares Issued	61	50	49	48	37	37	37	35	15	15	15	14
Shares Outstanding	61	50	49	48	37	37	37	35	15	15	15	14

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-4.81%	34.87%	52.75%	-	-	-	-	-	-	-	-	-
2025	29.56%	29.76%	40.06%	25.29%	51.65%	115.86%	8.98%	-0.11%	20.95%	66.65%	95.62%	82.96%
2024	-4.31%	-4.89%	-3.74%	40.54%	30.87%	55.78%	-17.35%	-18.87%	-47.56%	24.13%	0.20%	8.74%
2023	-	-	-	-	-	-	-12.25%	-11.27%	-20.10%	3.16%	12.03%	115.19%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	38.51	23.76	22.37	16.94	27.42	30.03	28.89	22.89	26.61	23.19	59.01	39.21
Quick Ratio	38.03	23.38	21.92	16.65	27.12	29.78	28.80	22.78	26.61	23.19	59.01	39.21
Working Capital	861.59M	378.62M	328.48M	334.20M	319.90M	340.36M	363.83M	394.91M	32.55M	35.09M	36.96M	37.90M
Leverage & Debt
Debt to Equity	0.02	0.04	0.04	0.05	0.04	0.03	0.04	0.06	-0.04	-0.22	0.02	0.03
Interest Coverage TTM	-	-	-	-	-224.77	-84.81	-60.03	-40.46	-33.07	-57.77	-	-
Debt Ratio	0.02	0.04	0.03	0.04	0.04	0.03	0.03	0.05	0.04	0.04	0.02	0.03
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-	-2.11	-2.31	-2.31	-2.37	-2.34	-4.99	-3.93	-9.95	-3.46	-0.37	-0.38
Free Cash Flow Per Share TTM	-1.66	-1.65	-1.94	-1.92	-2.16	-1.89	-3.46	-2.67	-4.35	-1.12	-0.35	-0.38
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	32.92%	19.06%	25.93%	72.16%	214.07%	782.08%	1,468.16%	988.35%	402.65%	38.38%	-46.21%	-62.41%
EPS Growth (1Y)	-8.38%	-10.06%	-53.65%	-41.34%	-76.14%	-32.32%	1,246.47%	944.60%	2,164.96%	523.52%	-46.23%	-62.41%
Valuation Metrics
P/E TTM	-43.74	-23.28	-13.11	-8.34	-4.72	-4.38	-3.89	-6.23	-2.48	-3.28	-29.62	-34.46
P/B TTM	5.21	5.56	2.93	1.74	1.37	1.17	0.85	1.07	-2.73	-5.15	4.27	4.92
Market Cap	5.81B	2.71B	1.38B	847.41M	471.90M	427.63M	325.55M	367.98M	79.05M	36.33M	158.16M	186.93M
Enterprise Value	5.54B	2.66B	1.34B	756.16M	406.50M	344.06M	263.97M	-42.89M	63.93M	8.58M	120.73M	148.45M
Calculated Values
Free Cash Flow TTM	-101.19M	-91.22M	-88.46M	-84.77M	-90.89M	-78.75M	-58.03M	-40.08M	-13.93M	-3.59M	-5.01M	-5.45M
Net Debt	-268.47M	-49.52M	-46.94M	-91.25M	-65.40M	-83.57M	-61.58M	-410.88M	-15.12M	-27.74M	-37.43M	-38.49M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-22Sale

Owner: Agarwal, Arjun

Title: Senior Vice President, Finance

Shares: 1,587

Price/Share: $81.08

Value: $128,673.96

Shares Owned: 15,312

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Quinlan, Paul T

Title: General Counsel

Shares: 733

Price/Share: $69.69

Value: $51,082.77

Shares Owned: 31,034

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Sandler, Laura Lee

Title: Chief Operating Officer

Shares: 600

Price/Share: $69.69

Value: $41,814.00

Shares Owned: 236,384

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Klein, Lawrence Otto

Title: Chief Executive Officer

Shares: 1,729

Price/Share: $69.69

Value: $120,494.01

Shares Owned: 925,580

Relationship: Director,Officer

Ownership: Direct

2026-06-15Sale

Owner: Goncalves, Joana

Title: Chief Medical Officer

Shares: 7,947

Price/Share: $69.53

Value: $552,554.91

Shares Owned: 32,718

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-22	Agarwal, Arjun	Officer	Senior Vice President, Finance	Direct	Sale	1,587	81.08	$128,673.96	15,312	4
2026-06-15	Quinlan, Paul T	Officer	General Counsel	Direct	Sale	733	69.69	$51,082.77	31,034	4
2026-06-15	Sandler, Laura Lee	Officer	Chief Operating Officer	Direct	Sale	600	69.69	$41,814.00	236,384	4
2026-06-15	Klein, Lawrence Otto	Director,Officer	Chief Executive Officer	Direct	Sale	1,729	69.69	$120,494.01	925,580	4
2026-06-15	Goncalves, Joana	Officer	Chief Medical Officer	Direct	Sale	7,947	69.53	$552,554.91	32,718	4
2026-06-15	Agarwal, Arjun	Officer	Senior Vice President, Finance	Direct	Sale	395	69.69	$27,527.55	16,899	4
2026-06-12	Dambkowski, Carl	Director	-	Direct	Sale	12,583	70.11	$882,194.13	38,743	4
2026-05-21	Dambkowski, Carl	Director	-	Direct	Sale	105,000	59.17	$6,212,850.00	73,743	4
2026-05-18	Agarwal, Arjun	Officer	Senior Vice President, Finance	Direct	Sale	10,290	59.76	$614,930.40	16,406	4
2026-05-15	Goncalves, Joana	Officer	Chief Medical Officer	Direct	Sale	7,000	62.50	$437,500.00	33,377	4
2026-05-01	Sandler, Laura Lee	Officer	Chief Operating Officer	Direct	Sale	5,000	65.59	$327,950.00	236,984	4
2026-04-15	Goncalves, Joana	Officer	Chief Medical Officer	Direct	Sale	7,000	66.56	$465,920.00	33,377	4
2026-03-16	Goncalves, Joana	Officer	Chief Medical Officer	Direct	Sale	7,641	41.14	$314,350.74	33,377	4
2026-03-16	Sandler, Laura Lee	Officer	Chief Operating Officer	Direct	Sale	600	41.30	$24,780.00	236,984	4
2026-03-16	Quinlan, Paul T	Officer	General Counsel	Direct	Sale	733	41.30	$30,272.90	31,767	4
2026-03-16	Agarwal, Arjun	Officer	Senior Vice President, Finance	Direct	Sale	395	41.30	$16,313.50	18,863	4
2026-03-16	Klein, Lawrence Otto	Director,Officer	Chief Executive Officer	Direct	Sale	1,729	41.30	$71,407.70	927,309	4
2026-03-02	Sandler, Laura Lee	Officer	Chief Operating Officer	Direct	Sale	5,000	33.54	$167,700.00	237,584	4
2026-02-17	Goncalves, Joana	Officer	Chief Medical Officer	Direct	Sale	7,000	32.54	$227,780.00	34,018	4
2026-01-15	Goncalves, Joana	Officer	Chief Medical Officer	Direct	Sale	7,000	31.90	$223,300.00	1,518	4
2026-01-02	Sandler, Laura Lee	Officer	Chief Operating Officer	Direct	Sale	13,000	29.00	$377,000.00	205,084	4
2025-12-19	Goncalves, Joana	Officer	Chief Medical Officer	Direct	Sale	7,000	30.11	$210,770.00	1,518	4
2025-02-14	Vhcp, Management Iii, Llc…	TenPercentOwner	-	Indirect	Purchase	88,794	11.44	$1,015,803.36	4,148,428	4
2024-08-16	Janus, Henderson Biotech …	TenPercentOwner	-	Indirect	Purchase	5,818	2.96	$17,221.28	2,117,213	4
2024-07-25	Janus, Henderson Group Pl…	TenPercentOwner	-	Indirect	Purchase	30,227	3.05	$92,192.35	2,111,395	4
2024-07-11	Janus, Henderson Biotech …	TenPercentOwner	-	Indirect	Purchase	94,537	3.45	$326,152.65	1,891,312	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

93.50%

Inst. Shares: 51,586,208

Shares Outstanding: 55,172,410

2025-12-31

111.02%

Inst. Shares: 50,639,739

Shares Outstanding: 45,614,142

2025-09-30

101.96%

Inst. Shares: 44,929,023

Shares Outstanding: 44,067,059

2025-06-30

80.57%

Inst. Shares: 33,917,857

Shares Outstanding: 42,095,951

2025-03-31

74.88%

Inst. Shares: 31,207,630

Shares Outstanding: 41,679,560

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	51,586,208	55,172,410	93.50%
2025-12-31	50,639,739	45,614,142	111.02%
2025-09-30	44,929,023	44,067,059	101.96%
2025-06-30	33,917,857	42,095,951	80.57%
2025-03-31	31,207,630	41,679,560	74.88%
2024-12-31	29,638,121	16,789,362	176.53%
2024-09-30	24,280,133	15,013,655	161.72%
2024-06-30	32,273,639	3,197,975	-
2024-03-31	7,120,496	3,197,977	222.66%
2023-12-31	7,419,922	14,415,877	51.47%
2023-09-30	3,206,946	14,410,143	22.25%
2023-06-30	2,784,860	14,410,143	19.33%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Oruka Therapeutics, Inc. (ORKA) — SEC Financial Statements & Analysis

Oruka Therapeutics, Inc. (ORKA) is a pharmaceutical preparations company, incorporated in DE. Oruka Therapeutics, Inc. trades on Nasdaq as: ORKA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Oruka Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.02x, a Price-to-Book (P/B) ratio of 5.21x (TTM), at a market cap of $5.81B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.02x
P/B TTM: 5.21x
Market Cap: $5.81B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Oruka Therapeutics, Inc. in?

Oruka Therapeutics, Inc. (ORKA) operates in the Pharmaceutical Preparations industry.

What is ORKA's market cap?

Oruka Therapeutics, Inc. (ORKA) has a market capitalization of $5.81B as of 2026-06-30.

What exchange does ORKA trade on?

Oruka Therapeutics, Inc. (ORKA) trades on the Nasdaq.

Where is Oruka Therapeutics, Inc. incorporated?

Oruka Therapeutics, Inc. is incorporated in DE.